

**Title:** A Physiologic approach to the pharmacogenomics of hypertension

by Michael T. Eadon<sup>1</sup>, Arlene B. Chapman<sup>2</sup>

Review article for journal: Advances in Chronic Kidney Disease

Tables: 1

Figures: 0

Disclosures: ABC is a consultant with Otsuka Pharmaceuticals and Kadmon.

Acknowledgments: MTE was supported by the PhRMA foundation (Clinical Pharmacology Young Investigator Award) and the Norman S. Coplon Satellite Health Extramural Grant Program.

### **Authors**

<sup>1</sup>Michael Eadon  
Assistant Professor of Medicine  
Indiana University School of Medicine  
Division of Nephrology and Clinical Pharmacology  
950 West Walnut Street R2, 202  
Indianapolis, IN 46202  
T: 317-274-2502  
email: [meadon@iupui.edu](mailto:meadon@iupui.edu)

<sup>2</sup>Arlene Chapman  
Professor of Medicine  
University of Chicago  
Section of Nephrology,  
[Achapman1@medicine.bsd.uchicago.edu](mailto:Achapman1@medicine.bsd.uchicago.edu)  
5841 S Maryland Ave,  
5100MC  
Chicago, IL 60637

Corresponding Author  
Arlene Chapman  
Professor of Medicine  
University of Chicago  
Section of Nephrology,  
[Achapman1@medicine.bsd.uchicago.edu](mailto:Achapman1@medicine.bsd.uchicago.edu)  
5841 S Maryland Ave,  
5100MC  
Chicago, IL 60637

## **Introduction**

Essential hypertension affects over 40 million Americans and is associated with significant morbidity and mortality. Blood pressure (BP) response to specific antihypertensive agents is highly variable with the mean BP response typically similar to the standard deviation of the response measured. Although physiologic pathways are known that regulate BP and BP response to specific classes of antihypertensive agents, the management of patients with essential hypertension has suffered from a “hit or miss” approach and BP control rates remain low, at approximately 40% in the general population. Demographic characteristics including age, gender, and ethnicity are informative regarding the selection of class of antihypertensive agent; however, other variables (including genotype) that predict BP response are lacking. In part, measures of relative activation of the renin-angiotensin-aldosterone system (RAAS) including plasma renin activity, plasma renin activity/aldosterone ratios, and plasma renin activity indexed for sodium intake have helped to guide selection choice of antihypertensive agent (typically diuretic vs. no diuretic), but significant variation in response to antihypertensive agents exists, even when these characteristics are included when using a specific class of antihypertensive agent.

Hypertension is a multifactorial disease with convergent and divergent physiologic-regulating systems contributing to its presence, severity, and pathways involved in pharmacologically mediated reduction in BP levels. Counter-regulatory systems play a significant role in the development of hypertension as well as response to therapy and establishing genetic predictors of antihypertensive response have been less than ideal. While candidate gene approaches and genome wide association studies are beginning to demonstrate validated genetic predictors of BP response to antihypertensive therapy, it is most likely that yet to be identified significant genetic predictors exist in the form of rare (<1% allele frequency) variants, copy number variation, intronic flanking polymorphisms, RNA variation, and finally that there is a high likelihood that BP response to a given antihypertensive agent is due to polygenic causes. In this review, we have

elected to review in a physiologically guided manner, the pharmacogenomics of hypertension and provide a review of available and published studies, including their findings reproducibility and their limitations (Table 1).

## Metabolism polymorphisms

Polymorphisms in genes encoding the enzymes responsible for phase I and phase II biotransformation contribute to inter-individual differences in antihypertensive drug pharmacokinetics. The cytochrome P450 enzymes are part of a microsomal metabolism system in the smooth endoplasmic reticulum that resides predominantly in hepatocytes and in other cells. These enzymes catalyze phase I non-synthetic metabolism of xenobiotics through oxidation, reduction, and hydrolysis. In contrast, phase II synthetic biotransformation enzymes catalyze the conjugation of drugs through glucuronidation, acetylation, sulfation, and methylation. The phase I and phase II metabolism of antihypertensive drugs often lead to their activation or deactivation.

Functional polymorphisms may modify either expression or function of metabolic enzymes that will ultimately influence the parent drug and metabolite concentrations. These concentration changes manifest as alterations in the pharmacogenetic response (BP response to a drug) and in pharmacokinetic parameters such as drug clearance, area under the curve (AUC), or maximum concentration ( $C_{max}$ ). During drug development, the United States Food and Drug Administration (FDA) provides regulatory guidance to pharmaceutical companies regarding both *in vitro* and *in vivo* drug metabolism and drug interaction studies. As a result, a drug's metabolic enzymes are often known and have received great attention in candidate gene analyses in order to explore relevant genotype-drug interactions.

Metoprolol is predominantly metabolized by CYP2D6. At least 74 variant alleles of CYP2D6 have been described, including non-functional and loss of or reduced function alleles<sup>1</sup>.

Individuals who are homozygous for the non-functional alleles are defined as poor metabolizers with a resultant extended half-life of metoprolol. Intermediate metabolizers are heterozygous for non-functional alleles or homozygous for reduced function alleles, while extensive (normal) metabolizers are homozygous or heterozygous for reference functional alleles. The functional

allele frequency for Caucasians is 71%, and for those of African and Asian ancestry is closer to 50%<sup>2</sup>. The FDA label of metoprolol succinate cautions that the CYP2D6 enzyme is absent (poor metabolizer status) in about 8% of Caucasians and about 2% of most other populations. Gene duplication is also not uncommon for CYP2D6, with 12 or more copies previously reported<sup>3</sup>. Individuals with increased CYP2D6 copy number are considered ultra-rapid metabolizers.

Variant alleles in poor and intermediate metabolizers of CYP2D6 have been associated with increased plasma metoprolol levels even after extended year-long dosing. Poor metabolizers also have corresponding changes in their ratio of metoprolol to alpha-hydroxy-metoprolol metabolite<sup>4</sup>. Some small studies have failed to reveal significant adverse events or BP effects associated with metabolizer status, despite changes in pharmacokinetic parameters<sup>5</sup>. However, a prospective, double-blind, longitudinal study of metoprolol use found significant differences in diastolic BP (DBP), QT interval, heart rate, and incidence of bradycardia<sup>6,7</sup>. As such, the Dutch pharmacogenomics working group (DPWG) has endorsed CYP2D6 screening with the use of metoprolol<sup>8</sup>. The group recommends selection of an alternate drug or a 75% dose reduction in poor metabolizers, 50% dose reduction in intermediate metabolizers, and titration up to a maximum of 250% of the normal dose in ultra-rapid metabolizers.

The role of CYP2D6 has been explored with other beta-blockers, including carvedilol. Genotype appears to affect carvedilol clearance and concentration<sup>9,10</sup>. Analogously, genotype is a predictor of drug dose in retrospective analyses<sup>11</sup>. However, alterations in clinical phenotype or therapy response have not been observed<sup>10,11</sup>. Variant alleles in UGT1A1 have also been shown to alter clearance and glucuronidation of carvedilol, without affecting clinical phenotype<sup>12</sup>.

Other cytochrome P450 enzymes similarly alter antihypertensive medication metabolism.

Losartan is a prodrug metabolized into its active carboxylic acid metabolite by CYP2C9 and CYP3A4. The metabolite is predominantly responsible for the angiotensin II receptor antagonism

of losartan. Losartan's FDA label cautions that in approximately 1% of individuals, minimal conversion of losartan to the active metabolite occurs. *In vitro* studies have suggested CYP2C9 contributes to losartan metabolism to a greater extent than CYP3A4<sup>13</sup>. Candidate pharmacogenomic analyses have illustrated that the CYP2C9\*3 reduced function allele is associated with decreased formation of losartan's active metabolite<sup>14,15</sup>. Limited clinical data is available to confirm pharmacodynamic effects. However, associations have been uncovered between the \*3 allele and less favorable BP and proteinuria reduction in Caucasians with chronic kidney disease (CKD)<sup>16</sup>. In the Losartan Intervention for Endpoint reduction in Hypertension study, homozygotes with the \*2 allele had decreased losartan response; however, this association did not remain significant after adjusting for multiple-testing<sup>17</sup>.

Data regarding amlodipine and verapamil is less convincing. These calcium channel blockers are known to be metabolized by CYP3A4 and CYP3A5 through drug interaction data. In a small Korean population, amlodipine concentrations (AUC and C<sub>max</sub>) were reduced in individuals with a CYP3A5\*1/\*1 genotype<sup>18</sup>. This data is the opposite of that expected and conflicts with *in vitro* data suggesting amlodipine is primarily metabolized by CYP3A4<sup>19</sup>. CYP3A5 genotypes have not been found to be associated with amlodipine efficacy<sup>18,20</sup>. Similarly, the CYP3A5\*3 and \*6 alleles were not significantly associated with verapamil response<sup>21</sup>. In contrast, the SNPs rs2740574 and rs2246709 affecting CYP3A4 metabolism were associated with target BP goals in the African-American Study of Kidney Disease and Hypertension Trial<sup>20</sup>. More studies are required to understand the clinical relevance of cytochrome P450 pharmacogenetics in calcium channel blocker metabolism.

Hydralazine undergoes phase II biotransformation by N-acetyltransferase 2. A slow acetylation phenotype is found in 90% of North Africans, 50% of Caucasians, and up to 30% of Asians<sup>22</sup>. The slow phenotype is associated with the NAT2\*5, \*6, and \*7 alleles. The FDA label of hydralazine warns that plasma levels of hydralazine vary widely among individuals. Patients with

\*5, \*6, and \*7 alleles will display higher plasma levels of hydralazine and the drug provides more efficacious BP control in individuals with these slow acetylator genotypes<sup>23</sup>. Currently, it is unclear whether slow acetylator genotypes also predict the development of adverse effects, such as hydralazine-associated systemic lupus erythematosus<sup>24</sup>.

### **Candidate pharmacodynamic polymorphisms of the renin-angiotensin system**

In contrast to metabolic variants that affect drug concentration and kinetics, genetic variation in receptors and intracellular targets of antihypertensive pathways mediate pharmacodynamic effects of drugs. These variants alter a compound's effect on a biologic system at a given drug concentration. Candidate variants affecting the signaling of the RAAS have been investigated in detail. However, none of these variants has been endorsed by the Clinical Pharmacogenomics Implementation Consortium (CPIC) or DPWG as ready for broad clinical implementation.

Polymorphisms of the RAAS remain attractive candidates for the study of pharmacogenomics and hypertensive drug response because of their physiologic plausibility. Variants associated with angiotensin-converting enzyme 1 and 2 (ACE1, ACE2), angiotensinogen (AGT), angiotensin II type 1 and 2 receptors (AT1, AT2), and renin (REN) have all been explored to varying extents. The most studied of these variants is rs1799752, an insertion and deletion genetic variant in intron 16 of the *ACE* gene (*ACE I/D*), with an insertion variant allele frequency of about 40–50%. The insertion variant has been associated with lower serum ACE levels, accounting for 47% of ACE level variance among individuals<sup>25</sup>. As a result, rs1799752 has been evaluated extensively as a predictor of ACE-inhibitor (ACEI) or angiotensin II receptor blocker (ARB) efficacy. Initial candidate studies showed increased ACEI and ARB response in individuals with the II genotype compared with the DD genotype<sup>26-32</sup>. These studies were marked by small sample sizes, significant inter-study heterogeneity, and disparate endpoints as markers of response. These

endpoints have ranged from improvement in measured hemodynamics to reduction in proteinuria to BP response. However, significant conflicting data have since been reported that reveal no association between rs1799752 and ACEI or ARB BP response<sup>17,33-39</sup>. Although evidence does not support the use of rs1799752 as a predictor of ACEI or ARB response, a few studies suggest this SNP may remain a predictor of diuretic response<sup>40-42</sup>. Additional investigation is required to confirm these results.

For variants in *AGT*, *AT1*, and *AT2*, most well-powered studies have failed to show consistent interactions between genotype and antihypertensive response<sup>17,34,35</sup>. In contrast, polymorphisms of *REN* have shown promise in Asian populations. The Renin C-5312T polymorphism was found to be a predictor of valsartan response. While C allele homozygotes do not have altered baseline plasma renin activity, the CC genotype is associated with both improved DBP response to valsartan and lower renal gene expression of *REN*<sup>34,43</sup>. After 5 months of valsartan therapy, a second study revealed reflexive rises in serum renin levels were higher in patients with the CT/TT genotypes<sup>44</sup>. This study also replicated the greater DBP response in C allele homozygotes in the small but independent cohort. An additional variant of *REN*, rs11240688, was associated with HCTZ-induced BP reduction<sup>45</sup>. It remains to be understood whether these results can be extrapolated to populations without Asian ancestry.

### **Candidate pharmacodynamic polymorphisms of adrenergic response**

Beta-adrenergic receptor blockade endures as a mainstay in the treatment of hypertension, congestive heart failure, and cardiac arrhythmia. Adrenoceptor  $\beta$ 1 and  $\beta$ 2 stimulation increases intracellular cyclic adenosine monophosphate (cAMP) production, augmenting cardiomyocyte contractility and chronotropy. Adrenoceptor  $\beta$ 3 stimulation mitigates these effects. These adrenoceptors are G-protein-coupled receptors that initiate intracellular signaling cascades. G-



protein-coupled receptor Kinase 4 (GRK4) mediates phosphorylation of the adrenoreceptors, inhibiting cAMP production. Polymorphisms involved in the signal transduction and receptor antagonism of the adrenergic system have received considerable attention. Variants associated with expression of, function of, or chromosomal proximity to *ADRB1*, *ADRB2*, *ADRB3*, and *GRK4* have all been implicated as predictors of antihypertensive response.

The most studied variant of *ADRB1*, rs1801253, is a missense coding polymorphism that results in a single amino acid substitution of glycine for arginine with the G allele. The SNP has a minor allele frequency of 29.8% for the G allele. In a large dataset of over 86,000 patients, the C allele was associated and replicated with increased baseline systolic blood pressure (SBP) and DBP.<sup>46</sup> The association of this allele with antihypertensive response to beta-blocker therapy is less straight forward. Several small studies have revealed positive results with the C allele corresponding to an improved response to beta-blockade as defined by reduction in BP or heart failure endpoints<sup>47-51</sup>. Studies have also illustrated contradictory results where the G allele is associated with more favorable rate control with verapamil and multiple beta-blockers<sup>52</sup>. However, negative studies, including larger, well-powered investigations, predominate suggesting that rs1801253 cannot reliably predict antihypertensive response, rate control, or heart failure outcomes<sup>11,17,53-58</sup>.

Adrenoceptor- $\beta_2$  agonism is not specific to cardiomyocytes, as its principle effect in bronchial epithelial cells is to facilitate smooth muscle relaxation and bronchodilation. Variants of *ADRB2* have been associated with asthma exacerbations and salmeterol response<sup>59,60</sup>. However, antihypertensive and cardiac investigations of beta-blockers and ACEIs have yielded mixed results of the *ADRB2* variants, rs1042713 and rs1042714, in predicting BP and congestive heart failure responses<sup>10,17,56,57,61-63</sup>. Rs4994, a polymorphism in *ADRB3*, has been evaluated in hypertensive studies. This variant is associated with essential hypertension in Han Chinese<sup>64</sup>,

mean thiazide BP response in Japanese individuals<sup>65</sup>, and pulse pressure variation between atenolol and losartan in whites<sup>17</sup>. These associations were not corrected for a multiple testing penalty and have not been replicated. Presently, no variants in *ADRB1*, *ADRB2*, or *ADRB3* have been recommended for routine screening by CPIC or the DPWG.

The adrenergic signaling cascade intermediates, GRK4 and G-protein subunit  $\beta 3$  (*GNB3*), are promising mediators of antihypertensive response. The SNP rs1024323 is a missense variant of GRK4 with a minor allele frequency of 37%. In the African American Study of Kidney Disease and Hypertension (AASK) trial, the CC genotype of rs1024323 was associated with metoprolol BP response. However, the association was only significant in men who were heterozygous or homozygous for the rs2960306 T allele as well<sup>66</sup>. Significant associations were not found in women or in men homozygous for the rs2960306 G allele. These results have been replicated in a mixed gender population of whites and Hispanics in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) trial and the International Verapamil SR/Trandolapril Study (INVEST-GENES). These trials similarly found that the haplotype consisting of the C allele of rs1024323 and T allele of rs2960306 were associated with greater atenolol-induced DBP reduction<sup>67</sup>. This haplotype was also associated with improved cardiovascular outcomes independent of the BP effect. These associations were additive and stronger in individuals with the rs1801253 CC genotype of *ADRB1*, supporting the polygenic nature of hypertension.

Several SNPs associated with the G-protein subunit  $\beta 3$  (*GNB3*) have been associated with beta-blocker, clonidine, and diuretic response. A single trial suggested the C allele of variant rs5443 is associated with improved SBP response to atenolol<sup>54</sup>. This trial suggested that two additional SNPs, rs11064426 and rs2301339, were also associated with atenolol response. However, conflicting data have been reported; the T allele of rs5443 was found to be linked to greater heart rate attenuation<sup>68</sup> in a separate study. The T allele was also predictive of net sodium chloride and

calcium excretion in response to loop diuretic use in healthy volunteers<sup>42</sup>. The rs5443 T allele may further predict response to clonidine in cirrhotics and healthy individuals<sup>69,70</sup>; caution should be employed in interpreting these results as the studies were small and employed non-traditional endpoints.

In summary, variants of *ADRB1*, *ADRB2*, *ADRB3*, and *GNB3* have not been reproducibly associated with antihypertensive drug response. Data regarding polymorphisms of *GRK4*, particularly rs1024323 and rs2960306, are encouraging and warrant further investigation.

### **Candidate variants contributing to sodium reabsorption**

Linkage studies in hypertensive families have vaulted the chromosomal region near the neural precursor cell expressed developmentally downregulated 4-like gene (*NEDD4L*) to candidate gene status<sup>71</sup>. These investigations uncovered a variant (rs4149601) responsible for alternative splicing of *NEDD4L*. The alternative isoform I, from the A allele of rs4149601, led to decreased expression of the distal epithelial sodium channel (ENaC). Furthermore, the A allele was associated with lower DBP compared to the G allele.

Larger candidate gene investigations have both replicated and contradicted these findings. For example, in the Nordic Diltiazem Study (NORDIL), the G allele of rs4149601 was a predictor of thiazide and atenolol response over diltiazem response without consideration of other loci<sup>72</sup>. In contrast, it was the A allele of rs4149601 that was found to predict thiazide responsiveness in a case-control study of hypertensive Chinese subjects<sup>73</sup>. One explanation is that the rs4149601 locus does not fully explain the hypertensive phenotype alone, as additional cotransmitted loci may augment or mitigate the effects observed. In the initial linkage analyses, rs4149601 was only partially causative and the presence of a second intronic variant (rs2288774) was required to

account for significant differences in SBP<sup>71</sup>. In the PEAR and INVEST trials, a haplotype consisting of the G allele of rs4149601 and C allele of a second SNP rs292449 predicted greater BP response to hydrochlorothiazide as well as adverse cardiovascular outcomes in whites not treated by hydrochlorothiazide<sup>74</sup>.

Polygenic drug-gene interactions may also be required to explain phenotypic variation. An Italian study evaluated the *NEDD4L* variant in concert with variants of other genes involved in sodium reabsorption, *WNK1* rs880054 and alpha-adducin (*ADD1*) rs4961<sup>75</sup>. The combination of the *ADD1* T allele, the *WNK1* G (T) allele, and the *NEDD4L* A allele was consistently associated with improved BP response to a saline load and greater urinary sodium excretion. As expected, these individuals were also the least responsive to thiazide diuretic-induced BP reduction. The *ADD1* variant rs4961 has been studied extensively on its own. However, results have been conflicting as the T allele has been found to confer increased diuretic efficacy in some studies, but reduced efficacy in others<sup>42,75-84</sup>.

### **Plausible variants uncovered in unbiased analyses**

Knowledge of antihypertensive pharmacogenomics has been greatly expanded by candidate gene exploration into the RAAS, adrenergic, and sodium reabsorption pathways. However, the field has been reinvigorated by more recent unbiased investigations in large, hypertensive cohorts. Many of these investigations began as genome-wide association studies (GWAS) that were later replicated or linked to physiologic relevant functional evidence. Several examples of these novel variants are illustrated below.

A GWAS of atenolol and metoprolol BP response was conducted in a cohort of African-American, hypertensive participants from the PEAR studies<sup>85</sup>. Two replicated variants,

rs201279313 in *SLC25A31* and rs11313667 in *LRRC15*, were found to predict improved BP response to  $\beta$ -blocker monotherapy in African Americans. *SLC25A31* encodes a mitochondrial ADP/ATP carriers, while *LRRC15* encodes the leucine-rich repeat containing receptor-like kinase protein 15, whose function is not well characterized. Neither of these variants would have been discovered without an unbiased approach.

Analogously, a GWAS examining atenolol monotherapy was conducted in white participants of the PEAR trials<sup>86</sup>. This analysis identified two polymorphisms, rs12346562 and rs1104514, near the *PTPRD* gene that were associated with improved atenolol BP reduction in whites. *PTPRD* encodes protein-tyrosine phosphatase delta, a signaling molecule that regulates cell growth and differentiation. The significance of rs12346562 was replicated in a cohort of Finnish men from the genetics of drug responsiveness in essential hypertension study (GENRES)<sup>87</sup>. Three other independent groups of hypertensive individuals were examined as part of the replication and validation process. Several other variants of *PTPRD* were identified as significant in these populations, including rs10739150 in black, hypertensive individuals.

An initial GWAS of patient samples from the GERAS trial<sup>88</sup> identified a SNP in *YEATS4*, rs7297610, as a significant predictor of DBP response to hydrochlorothiazide in a mixed population of Caucasians and African Americans<sup>89</sup>. *YEATS4* encodes the YEAT domain-containing protein 4, a transcription factor that aids in gene activation through acetylation of nucleosomal histones H4 and H2A. The association was replicated in the PEAR trial cohort and functional evidence of its direct role in the pathogenesis of hypertension has been proposed<sup>90</sup>. The leukocyte expression of *YEATS4* significantly declines following hydrochlorothiazide treatment in African Americans homozygous for the C allele. Baseline *YEATS4* expression was also lower in T carriers as opposed to C allele homozygotes. These expression data add functional relevance to the role of rs7297610 as a predictor and mediator of hydrochlorothiazide response.

A combined association study of the PEAR, GERAS, and NORDIL trials highlighted a significant variant of *PRKCA*, protein kinase C alpha, as significantly associated with DBP reduction in response to thiazides<sup>91</sup>. The SNP, rs16960228, was replicated in the GENRES study cohort. Individuals treated with thiazides had a 4.16 mm Hg increased reduction of DBP per A allele.

In summary, these variants identified from unbiased GWAS teach us a great deal about the underlying pathogenesis of hypertension. All of these variants have been replicated and some also have corresponding functional evidence to corroborate their significance. These data reveal a vibrant culture of discovery in the field. Randomized, controlled trials and implementation efforts are now required to translate these innovations into clinical practice.

## **Implementation**

CPIC and DPWG are collaboratives that curate the literature and produce clinical guidelines with information necessary for clinical implementation. These recommendations are available in the Pharmacogenomics Knowledgebase (PharmGKB, [www.pharmgkb.org](http://www.pharmgkb.org)), but significant barriers to the broad adoption of pharmacogenetic testing in clinical practice remain<sup>92</sup>. These barriers include genotyping logistics to provide rapid results; a dearth of prospective, randomized, clinical trials; clinician inexperience with pharmacogenomics; inconsistent reimbursement of pharmacogenomic screening; and a lack of consensus regarding treatment algorithms and professional society recommendations. In order to expend the resources to overcome these obstacles, genetic biomarkers must hold value over and above traditional biomarkers in clinical practice.

The inherent properties of antihypertensive agents magnify some of the obstacles delineated above. These drugs are inexpensive, low in toxicity, frequently titrated, and easily monitored. Traditional biomarkers of efficacy and toxicity such as BP, pulse, and urine output are reliable and readily assessed in clinic. Other adverse events such as hyperuricemia or hypokalemia can be transient and would require serologic monitoring with or without genetic testing. Furthermore, the sheer number of alternative agents allows clinicians the opportunity to optimize a patient's regimen based on trial and error. Although some of the variants discussed in this review are considered of sufficient importance to warrant listing within FDA package inserts, most tests are not routinely reimbursed by the Centers of Medicare and Medicaid Services. Finally, the polygenic nature of hypertension adds complexity to the interpretation of pharmacogenetic testing. These obstacles are reflected in the relative paucity of recommendations for routine use of pharmacogenomic screening in the treatment of hypertension. Presently, CPIC and DPWG have recommended only one genetic screening test for routine use: CYP2D6 screening for metoprolol (DPWG).

Despite these impediments, the opportunity to benefit patients and practitioners is readily apparent. Hypertension is among the most commonly treated diseases worldwide. The American Society of Hypertension has noted that in many communities, fewer than half of all hypertensive patients have adequately controlled BP<sup>93</sup>. For some patients, serial follow-up may be required to develop an adequate regimen. Thus, selecting the right agent first may net cost savings to health systems by decreasing required follow-up and reducing adverse events. Indeed, the emphasis of this review has been on drug efficacy and agent selection. However, there is significant evidence supporting variants predicting adverse events including the hyperuricemia of thiazide use<sup>94</sup>, bradycardia associated with  $\beta$ -blockers<sup>5-8,95,96</sup>, and ACEI-related cough<sup>97</sup>.

Pharmacogenomic implementation efforts are underway at universities across the United States<sup>98-102</sup>; yet, few of these programs place emphasis on translating genetic predictors of antihypertensive drug efficacy or toxicity. Two distinct models of implementation may be discerned from these programs. The first is to implement screening for well-defined CPIC- and/or DPWG-endorsed variants broadly across an entire health care system. Examples include the programs at St. Jude Children’s Research Hospital<sup>98</sup> and Indiana University’s Eskenazi Health System<sup>102</sup>. Since the genetic test results are available to all practitioners, clear evidence-based dosing algorithms are required to inform clinicians who may have limited prior experience with pharmacogenomic test interpretation. Neither of these programs provides testing for variants with lower levels of evidence. Few variants related to antihypertensive agents meet these evidence thresholds.

An alternative model of pharmacogenomic implementation includes screening for investigational variants, but restricts the results to a small population of physicians with significant understanding of pharmacogenomics. A successful example of this program is found in University of Chicago’s “1,200 Patient’s Project”<sup>101</sup>. The University of Chicago’s open array platform includes screening of variants for hydrochlorothiazide (*REN* and *ADD1*), amlodipine (*CYP3A4* and *CACNA1C*), metoprolol (*ADRB1* and *GRK4*), and atenolol (*LDLR*, *GNB3*, and *AGT*). Most CLIA-approved pharmacogenomic laboratories utilize custom PCR-based OpenArray<sup>TM</sup> platforms for genotyping. These arrays assess up to 64 variants in a single individual. Given the polygenic nature of hypertension, the using pharmacogenomics as a tool to assist in hypertensive therapy selection lends itself to having a panel of already-available genetic variants in the medical record. The clinical functionality decreases if the genetic screening is prompted by a new antihypertensive agent prescription. Although the cost of genotyping has declined, broad-based genetic screening has not become universal. Until that time, further



randomized, controlled trials are required to validate the utility of genetic variants associated with antihypertensive traits.

Table 1: Description of key pharmacogenomics of hypertension studies by antihypertensive agent.

Class / Drug	Gene	Variant	Allele	Level of Evidence	Clinical Significance	Ref
Hydralazine	<i>NAT2</i>	*5,*6,*7,*14		FDA label	Homozygotes for slow acetylation alleles (*5, *6, *7, *14) have greater response to hydralazine.	23
Beta-Blockers	<i>ADRB1</i>	rs1801253	G > C	Conflicting data	CC genotype may predict increased response to beta-blockers and non-dihydropyridine CCBs	11,46-55,57,58,103-109
	<i>GRK4</i>	rs2960306	G > T	Replicated	T allele predicts reduced atenolol and metoprolol efficacy	66,67
	<i>GRK4</i>	rs1024323	C > T	Single study data	CC genotype predicts reduced metoprolol efficacy in black males with TC/TT rs2960306 genotype	66
	<i>SLC25A31</i>	rs201279313	*del	Replicated	The deletion allele was associated with greater BP reduction after β-blocker treatment	85
	<i>LRRK15</i>	rs11313667	*del	Replicated	The deletion allele was associated with better BP response to β-blocker monotherapy	85
	<i>PTPRD</i>	rs12346562	A > C	Replicated	A allele associated with improved BP response to atenolol	86
Metoprolol	<i>CYP2D6</i>	*2,*3,*4, etc.		DPWG guideline	Poor metabolizers require dose reduction and are at risk for bradycardia	5-8,95,96
Atenolol	<i>LDLR</i>	rs688	C > T	Single study data	TT genotype predicts reduced atenolol efficacy (N = 49)	110
	<i>FTO</i>	rs9940629	A > G	Single study data	Caucasians with AA genotype had smaller HDL reductions in response to atenolol (N = 232)	111
		rs12595985	C > A	Single study data	African Americans with AA genotype had higher HDL cholesterol with atenolol (N = 152)	111
	<i>PLA2G4A</i>	rs1015710	G > C	Single study data	CC genotype predicts higher HDL cholesterol in whites using atenolol (N = 232)	111
	<i>PTGS2</i>	rs4648287	A > G	Single study data	GG genotype predicts higher HDL cholesterol in African Americans using atenolol (N = 152)	111
	<i>ABCB1</i>	rs3213619	A > G	Single study data	GG genotype of rs3213619 and rs10267099 predict higher HDL cholesterol in African Americans	111
	<i>PROX1</i>	rs340874	T > C	Single study data	C allele is associated with increased fasting glucose in whites using atenolol	112
	<i>GALNT2</i>	rs2144297	T > C	Single study data	TT genotype predicts higher HDL cholesterol in African Americans using atenolol (N = 152)	111
	<i>GALNT2</i>	rs2144300	C > T	Single study data	CC genotype predicts higher HDL cholesterol in whites using atenolol (N = 232)	111
Carvedilol	<i>CYP2D6</i>	*2,*3,*4, etc.		FDA label	Asian poor metabolizers of CYP2D6 have increased concentrations of carvedilol	8,9,113

	<i>UGT1A1</i>	*6, *28		Conflicting data	*28 allele predicts increased and *6 predicts decreased glucuronidation of carvedilol	11,12
<b>Angiotensin II Receptor Blockers</b>	<i>CYP11B2</i>	rs1799998	A > G	Conflicting data	AA genotype predicts reduced response to candesartan, but increased response to benazepril or imidapril in Asians.	114,115
Losartan	<i>STK39</i>	rs6749447	T > G	Single study data	TT genotype predicts increased losartan response in whites (N = 202)	116
	<i>CYP2C9</i>	rs1057910	C > A	FDA label	*2 and *3 allele associated with decreased losartan effect, metabolism and metabolite appearance	13,14,17
Irbesartan	<i>APOB</i>	rs1367117	G > A	Single study data	AA genotype predicts reduced irbesartan response in whites (N = 48)	110
Valsartan	<i>REN</i>	C-5312T	C > T	Replicated	CC genotype predicts improved valsartan response and lower renal expression of <i>REN</i> .	34,43,44
<b>ACE Inhibitors</b>	<i>AGTR1</i>	rs5182	C > T	Single study data	CC genotype predicts increased cardiovascular event risk with ACEI use (N = 786)	117
	<i>AGTR1</i>	rs5186	A > C	Conflicting data	AA genotype may predict improved ACEI + ARB response and cardiovascular event risk	30,117,118
	<i>BDKRB2</i>	rs1799722	C > T	Conflicting data	TT genotype may confer increased risk of ACEI-related cough in Asians (2 of 4 studies positive) and decreased enalapril response	119-123
		rs8012552	C > T	Single study data	TT genotype confers lower risk of ACEI-related cough (N = 106)	97
	<i>PTGER3</i>	rs11209716	T > C	Single study data	CC genotype confers lower risk of ACEI-related cough (N = 249)	97
	<i>ABO</i>	rs495828	T > G	Replicated	TT genotype predicts development of cough with ACEI treatment	124,125
Enalapril	<i>VEGFA</i>	rs699947	A > C	Single study data	AA genotype predicts increased response to enalapril (N = 54)	126
	<i>NR3C2</i>	rs5522	C > T	Single study data	TT genotype predicts increased enalapril response in Asians (N = 263)	127
Ramipril	<i>ACE</i>	rs4344	G > A	Single study data	Homozygosity of either allele predicts increased ramipril response (N = 347)	128
		rs4359	T > C	Single study data	Homozygosity of either allele predicts increased ramipril response (N = 347)	128
Benazepril	<i>AGT</i>	rs7079	G > T	Single study data	TT genotype predicts increased benazepril response in Chinese	129
	<i>AGT</i>	rs4762	G > A	Single study data	G allele predicts increased benazepril response in Asians	129
	<i>PRCP</i>	rs2229437	T > G, A	Single study data	TT genotype predicts increased benazepril response in Asians (N = 1092)	130
<b>Calcium Channel Blocker</b>	<i>TANC2</i>	rs2429427	G > A	Single study data	GG genotype predicts increased BP response to calcium channel blockers in Asians (N = 93)	131
	<i>CACNA1</i>	rs2239128	T > C	Single study data	CC genotype predicts increased calcium channel blocker BP response in whites (N = 120)	132

	<i>C</i>					
		rs2238032	T > G	Single study data	TT genotype predicts increased calcium channel blocker BP response in whites (N = 120)	132
Diltiazem	<i>PLCD3</i>	Rs12946454	A > T	Single study data	A allele predicts improved BP response for white diltiazem users in NORDIL trial (N = 1990)	133
Verapamil	<i>KCNIP1</i>	rs2301149	C > G	Single study data	GG genotype predicts increased cardiovascular events with verapamil use compared to CC or CG	134
		rs11739136	C > T	Replicated	T allele confers improved BP control with verapamil	134-136
	<i>NR1H3</i>	rs2279238	C > T	Single study data	Verapamil use in TT genotype associated with increase in death, myocardial infarction, or stroke	137
		rs12221497	G > A	Single study data	Verapamil use in GG genotype associated with increase in death, myocardial infarction, or stroke	137
	<i>NOS1AP</i>	rs10494366	T > G	Single study data	GG genotype predicts increased risk of QTc prolongation in whites (N = 7565)	138
Amlodipine	<i>CYP3A5</i>	rs776746	T > C	Single study data	*1/*1 genotype predicts lower amlodipine AUC and Cmax in Korean males (N = 40)	18
	<i>CYP3A4</i>	rs2246709	A > G	Single study data	G allele predicts increased efficacy of amlodipine in African Americans (N = 145)	20
		rs2740574	C > T	Single study data	T allele genotype predicts increased efficacy in African American women	62
Nifedipine	<i>SLC14A2</i>	rs3745009	G > A	Single study data	GG genotype predicts greater BP reduction in Asians using nifedipine (N = 405)	139
		rs1123617	G > A	Single study data	AA genotype predicts greater BP reduction in Asians using nifedipine (N = 405)	139
<b>Thiazides</b>	<i>PRKCA</i>	rs4791040	T > C	Conflicting data	TT genotype predicts reduced thiazide response in NORDIL, but not PEAR and GERA trials	91
	<i>TLE1</i>	rs2378479	G > T	Replicated	T allele is associated with BP response in African Americans	**
Hydrochlorothiazide	<i>KCNJ1</i>	rs675388	G > A	Single study data	A allele predicts increase in fasting glucose during HCTZ use	140
		rs658903	T > A	Single study data	TT genotype predicts increased risk of DM in Hispanics (N = 464)	140
		rs59172778	A > G	Single study data	AA genotype predicts lower serum potassium	140
		rs12795437	G > C	Single study data	CC genotype predicts increased risk of DM in whites and Hispanics (N = 835)	140
		rs11600347	C > A	Single study data	AA genotype predicts increased risk of DM in whites and Hispanics (N = 835)	140
	<i>PRKCA</i>	rs16960228	G > A	Replicated	AA genotype predicts increased response to HCTZ in whites	91
	<i>YEATS4</i>	rs7297610	C > T	Replicated	TT genotype predicts decreased HCTZ response and decreased whole blood YEATS4 expression in African Americans	89,90

	<i>WNK1</i>	rs880054	C > T	Single study data	TT genotype predicts decreased SBP response to atenolol (N = 193)	75
	<i>LUC7L2</i>	rs6947309	C > T	Single study data	T Allele predicts higher uric acid levels with HCTZ use (N = 276)	94
	<i>FTO</i>	rs4784333	C > G	Single study data	C allele predicts higher uric acid levels with HCTZ use (N = 276)	94
	<i>TCF7L2</i>	rs4506565	A > T	Single study data	TT genotype predicts increased risk of DM in whites using HCTZ (N = 1435)	141
		rs4132670	G > A	Single study data	AA genotype predicts increased risk of DM in whites using HCTZ (N = 1435)	141
		rs7917983	T > C	Single study data	TT genotype predicts increased risk of DM in whites using HCTZ (N = 1435)	141
	<i>REN</i>	rs11240688	C > T	Single study data	CC genotype predicts improved response to thiazide diuretics in Asians (N = 90)	45
<b>Cross-Class Variants</b>						
Atenolol, ACEI/ARB	<i>AGT</i>	rs5051	C > T	Single study data	TT genotype predicts greater atenolol response (white), but reduced ACEI response (Asian)	142,143
	<i>AGT</i>	rs699	A > G	Conflicting data	GG genotype may predict greater SBP reduction and LVH decrease with atenolol/ irbesartan, but there is conflicting data for response to ACEI.	30,129,142, 144-148
BB, CCB, ACEI/ARB	<i>AGTR1</i>	rs5186	A > C	Conflicting data	AA genotype predicts increased response to HCTZ, nitrendipine, and candesartan, but poorer response to perindopril, captopril, irbesartan, and inconclusive results for losartan and quinapril	30,117,118, 144,146,148 -153
BB, CCB,ACEI, diuretic	<i>ADD1</i>	rs4961	G > T	Conflicting data	T allele confers increased diuretic efficacy in some studies and decreased efficacy in others	ADD1 <sup>42</sup> ,75-84
	<i>ACE</i>	rs1799752	*del	Replicated with conflicting data	del/del genotype predicts increased diuretic response and may decrease RAAS blockade response	26- 42,117,144, 154-165
	<i>ACE2</i>	rs2106809	A > G	Single study data	GG genotype is associated with increased captopril efficacy, but decreased response to other drugs	166
	<i>NOS3</i>	rs2070744	C > T	Replicated	CC genotype predicts resistant hypertension to a variety of drugs	167,168
CCB, thiazide	<i>CLCN6</i>	rs5065	A > G	Single study data	GG genotype predicts greater thiazide response compared to amlodipine (N = 38,462)	169
Atenolol, verapamil	<i>CACNA1C</i>	rs1051375	G > A	Single study data	AA genotype predicts fewer cardiovascular events with atenolol compared to verapamil	170
	<i>NR1H3</i>	rs111039149	A > G	Single study data	GG genotype associated with increased cardiovascular events with verapamil or atenolol	137
Atenolol, HCTZ	<i>NEDD4L</i>	rs75982813	A > G	Replicated	GG genotype predicts improved BP response to atenolol and HCTZ in whites (N = 767)	74

	<i>NEDD4L</i>	rs292449	G > C	Single study data	CC + CG genotype predicts improved BP response to HCTZ in whites (N = 767)	<sup>74</sup>
BB, CCB, diuretics	<i>NEDD4L</i>	rs4149601	G > A	Replicated	AA genotype predicts adverse cardiovascular events and reduced BP response in whites in PEAR (N = 767), INVEST (N = 1345), and NORDIL (N = 2594) trials, but greater BP response in Asians.	<sup>72-75</sup>
CCB, ACEI	<i>PTPRD</i>	rs4742610	C > T	Replicated	TT genotype predicts resistant hypertension in whites and Hispanics	<sup>86</sup>
Thiazide, ACEI	<i>MMP3</i>	rs3025058	A > del	Single study data	AA genotype predicts increased stroke risk in ALLHAT study with Lisinopril over chlorthalidone	<sup>171</sup>

Abbreviations: Ref, reference; BP, blood pressure; BB, beta-blocker; CCB, calcium channel blocker; ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blocker; AUC, area under curve; Cmax, maximum concentration; HCTZ, hydrochlorothiazide; DM – diabetes mellitus; DPWG, Dutch pharmacogenomics working group recommendation; Replicated, replicated in multiple studies, studies may have large or small effect size. FDA label, pharmacogenomics mentioned in the FDA drug label.

## References:

1. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. *Clin Pharmacokinet.* 2009;48(11):689-723.
2. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. *Pharmacogenomics.* 2002;3(2):229-243.
3. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. *Proc Natl Acad Sci U.S.A.* 1993;90(24):11825-11829.
4. Rau T, Heide R, Bergmann K, et al. Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. *Pharmacogenetics.* 2002;12(6):465-472.
5. Zineh I, Beitelshes AL, Gaedigk A, et al. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. *Clin Pharmacol Ther.* 2004;76(6):536-544.
6. Rau T, Wuttke H, Michels LM, et al. Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. *Clin Pharmacol Ther.* 2009;85(3):269-272.
7. Hamadeh IS, Langaee TY, Dwivedi R, et al. Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate. *Clin Pharmacol Ther.* 2014;96(2):175-181.
8. Swen JJ, Nijenhuis M, de Boer A, et al. Pharmacogenetics: from bench to byte--an update of guidelines. *Clin Pharmacol Ther.* 2011;89(5):662-673.
9. Takekuma Y, Takenaka T, Kiyokawa M, et al. Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis. *Biol Pharm Bull.* 2007;30(3):537-542.
10. Sehr D, Meineke I, Tzvetkov M, Gultepe S, Brockmoller J. Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB1 pharmacogenetics. *Pharmacogenomics.* 2011;12(6):783-795.
11. Baudhuin LM, Miller WL, Train L, et al. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure. *Am J Cardiol.* 2010;106(3):402-408.
12. Takekuma Y, Takenaka T, Kiyokawa M, et al. Contribution of polymorphisms in UDP-glucuronosyltransferase and CYP2D6 to the individual variation in disposition of carvedilol. *J Pharm Pharm Sci.* 2006;9(1):101-112.
13. Yasar U, Tybring G, Hidestrand M, et al. Role of CYP2C9 polymorphism in losartan oxidation. *Drug Metab Dispos.* 2001;29(7):1051-1056.
14. Yasar U, Forslund-Bergengren C, Tybring G, et al. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. *Clin Pharmacol Ther.* 2002;71(1):89-98.
15. Bae JW, Choi CI, Lee HI, Lee YJ, Jang CG, Lee SY. Effects of CYP2C9\*1/\*3 and \*1/\*13 on the pharmacokinetics of losartan and its active metabolite E-3174. *Int J Clin Pharmacol Ther.* 2012;50(9):683-689.
16. Joy MS, Dornbrook-Lavender K, Blaisdell J, et al. CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases. *Eur J Clin Pharmacol.* 2009;65(9):947-953.
17. Nordestgaard BG, Kontula K, Benn M, et al. Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study. *Pharmacogenet Genomics.* 2010;20(2):77-85.
18. Kim KA, Park PW, Lee OJ, et al. Effect of CYP3A5\*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. *Clin Pharmacol Ther.* 2006;80(6):646-656.
19. Zhu Y, Wang F, Li Q, et al. Amlodipine metabolism in human liver microsomes and roles of CYP3A4/5 in the dihydropyridine dehydrogenation. *Drug Metab Dispos.* 2014;42(2):245-249.
20. Bhatnagar V, Garcia EP, O'Connor DT, et al. CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease. *Am J Nephrol.* 2010;31(2):95-103.
21. Langaee TY, Gong Y, Yarandi HN, et al. Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil. *Clin Pharmacol Ther.* 2007;81(3):386-391.
22. Autrup H. Genetic polymorphisms in human xenobiotica metabolizing enzymes as susceptibility factors in toxic response. *Mutat Res.* 2000;464(1):65-76.
23. Spinasse LB, Santos AR, Suffys PN, Muxfeldt ES, Salles GF. Different phenotypes of the NAT2 gene influences hydralazine antihypertensive response in patients with resistant hypertension. *Pharmacogenomics.* 2014;15(2):169-178.
24. Ladero JM. Influence of polymorphic N-acetyltransferases on non-malignant spontaneous disorders and on response to drugs. *Curr Drug Metab.* 2008;9(6):532-537.

25. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. *J Clin Invest.* 1990;86(4):1343-1346.
26. Kanazawa H, Hirata K, Yoshikawa J. Effects of captopril administration on pulmonary haemodynamics and tissue oxygenation during exercise in ACE gene subtypes in patients with COPD: a preliminary study. *Thorax.* 2003;58(7):629-631.
27. O'Toole L, Stewart M, Padfield P, Channer K. Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure. *J Cardio Pharmacol.* 1998;32(6):988-994.
28. Jacobsen P, Rossing K, Rossing P, et al. Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. *Kidney Int.* 1998;53(4):1002-1006.
29. Mizuiri S, Hemmi H, Inoue A, et al. Renal hemodynamic changes induced by captopril and angiotensin-converting enzyme gene polymorphism. *Nephron.* 1997;75(3):310-314.
30. Volkan-Salanci B, Dagdelen S, Alikasifoglu M, Erbas T, Hayran M, Erbas B. Impact of renin-angiotensin system polymorphisms on renal haemodynamic responsiveness to acute angiotensin-converting enzyme inhibition in type 2 diabetes mellitus. *J Renin Angiotensin Aldosterone Syst.* 2009;10(1):41-50.
31. Parving HH, Jacobsen P, Tarnow L, et al. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. *BMJ.* 1996;313(7057):591-594.
32. Trevelyan J, Needham EW, Morris A, Mattu RK. Comparison of the effect of enalapril and losartan in conjunction with surgical coronary revascularisation versus revascularisation alone on systemic endothelial function. *Heart.* 2005;91(8):1053-1057.
33. Woo KT, Chan CM, Choong HL, et al. High dose Losartan and ACE gene polymorphism in IgA nephritis. *Genomic Med.* 2008;2(3-4):83-91.
34. Konoshita T, Kato N, Fuchs S, et al. Genetic variant of the Renin-Angiotensin system and diabetes influences blood pressure response to Angiotensin receptor blockers. *Diabetes Care.* 2009;32(8):1485-1490.
35. Redon J, Luque-Otero M, Martell N, Chaves FJ, Investigators P. Renin-angiotensin system gene polymorphisms: relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients. *Pharmacogenomics J.* 2005;5(1):14-20.
36. Filigheddu F, Argiolas G, Bulla E, et al. Clinical variables, not RAAS polymorphisms, predict blood pressure response to ACE inhibitors in Sardinians. *Pharmacogenomics.* 2008;9(10):1419-1427.
37. Arnett DK, Davis BR, Ford CE, et al. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. *Circulation.* 2005;111(25):3374-3383.
38. Yu H, Zhang Y, Liu G. Relationship between polymorphism of the angiotensin-converting enzyme gene and the response to angiotensin-converting enzyme inhibition in hypertensive patients. *Hypertens Res.* 2003;26(11):881-886.
39. Harrap SB, Tzourio C, Cambien F, et al. The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition. *Hypertension.* 2003;42(3):297-303.
40. Li Y, Zhou Y, Yang P, et al. Interaction of ACE and CYP11B2 genes on blood pressure response to hydrochlorothiazide in Han Chinese hypertensive patients. *Clin Exp Hypertens.* 2011;33(3):141-146.
41. Schwartz GL, Turner ST, Chapman AB, Boerwinkle E. Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide. *Kidney Int.* 2002;62(5):1718-1723.
42. Vormfelde SV, Brockmoller J. The genetics of loop diuretic effects. *Pharmacogenomics J.* 2012;12(1):45-53.
43. Makino Y, Konoshita T, Omori A, et al. A Genetic Variant in the Distal Enhancer Region of the Human Renin Gene Affects Renin Expression. *PloS one.* 2015;10(9):e0137469.
44. Rohman MS, Dewi Satiti IA, Widodo N, Lukitasari M, Sujuti H. Genetic Variants of C-5312T REN Increased Renin Levels and Diastolic Blood Pressure Response to Angiotensin Receptor Blockers. *Int J Hypertens.* 2015;2015:930631.
45. Huang CC, Chung CM, Hung SI, et al. Genetic variation in renin predicts the effects of thiazide diuretics. *Eur J Clin Invest.* 2011;41(8):828-835.
46. Johnson AD, Newton-Cheh C, Chasman DI, et al. Association of hypertension drug target genes with blood pressure and hypertension in 86,588 individuals. *Hypertens.* 2011;57(5):903-910.



47. Johnson JA, Zineh I, Puckett BJ, McGorray SP, Yarandi HN, Pauly DF. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. *Clin Pharmacol Ther.* 2003;74(1):44-52.
48. O'Connor CM, Fiuzat M, Carson PE, et al. Combinatorial pharmacogenetic interactions of bucindolol and beta1, alpha2C adrenergic receptor polymorphisms. *PLoS one.* 2012;7(10):e44324.
49. Chen L, Meyers D, Javorsky G, et al. Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol. *Pharmacogenet Genomics.* 2007;17(11):941-949.
50. Liu J, Liu ZQ, Yu BN, et al. beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. *Clin Pharmacol Ther.* 2006;80(1):23-32.
51. Mialet Perez J, Rathz DA, Petrashevskaya NN, et al. Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. *Nature Med.* 2003;9(10):1300-1305.
52. Parvez B, Chopra N, Rowan S, et al. A common beta1-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation. *J Am Coll Cardiol.* 2012;59(1):49-56.
53. Suonsyrja T, Donner K, Hannila-Handelberg T, Fodstad H, Kontula K, Hiltunen TP. Common genetic variation of beta1- and beta2-adrenergic receptor and response to four classes of antihypertensive treatment. *Pharmacogenet Genomics.* 2010;20(5):342-345.
54. Filigheddu F, Argiolas G, Degortes S, et al. Haplotypes of the adrenergic system predict the blood pressure response to beta-blockers in women with essential hypertension. *Pharmacogenomics.* 2010;11(3):319-325.
55. Rau T, Dungen HD, Edelmann F, et al. Impact of the beta1-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients. *Clin Pharmacol Ther.* 2012;92(1):21-28.
56. Metra M, Covolo L, Pezzali N, et al. Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure. *Cardiovasc Drugs Ther.* 2010;24(1):49-60.
57. de Groote P, Helbecque N, Lamblin N, et al. Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. *Pharmacogenet Genomics.* 2005;15(3):137-142.
58. White HL, de Boer RA, Maqbool A, et al. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. *Eur J Heart Fail.* 2003;5(4):463-468.
59. Basu K, Palmer CN, Tavendale R, Lipworth BJ, Mukhopadhyay S. Adrenergic beta(2)-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol. *J Allergy Clin Immunol.* 2009;124(6):1188-1194 e1183.
60. Wechsler ME, Lehman E, Lazarus SC, et al. beta-Adrenergic receptor polymorphisms and response to salmeterol. *Am J Respir Crit Care Med.* 2006;173(5):519-526.
61. Kaye DM, Smirk B, Williams C, Jennings G, Esler M, Holst D. Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. *Pharmacogenetics.* 2003;13(7):379-382.
62. Huang G, Xing H, Hao K, et al. Beta2 adrenergic receptor gene Arg16Gly polymorphism is associated with therapeutic efficacy of benazepril on essential hypertension in Chinese. *Clin Exp Hypertens.* 2004;26(6):581-592.
63. Iaccarino G, Izzo R, Trimarco V, et al. Beta2-adrenergic receptor polymorphisms and treatment-induced regression of left ventricular hypertrophy in hypertension. *Clin Pharmacol Ther.* 2006;80(6):633-645.
64. Wang L, Zhang B, Li M, et al. Association between single-nucleotide polymorphisms in six hypertensive candidate genes and hypertension among northern Han Chinese individuals. *Hypertens Res.* 2014;37(12):1068-1074.
65. Matayoshi T, Kamide K, Takiuchi S, et al. The thiazide-sensitive Na(+)-Cl(-) cotransporter gene, C1784T, and adrenergic receptor-beta3 gene, T727C, may be gene polymorphisms susceptible to the antihypertensive effect of thiazide diuretics. *Hypertens Res.* 2004;27(11):821-833.
66. Bhatnagar V, O'Connor DT, Brophy VH, et al. G-protein-coupled receptor kinase 4 polymorphisms and blood pressure response to metoprolol among African Americans: sex-specificity and interactions. *Am J Hypertens.* 2009;22(3):332-338.
67. Vandell AG, Lobmeyer MT, Gawronski BE, et al. G protein receptor kinase 4 polymorphisms: beta-blocker pharmacogenetics and treatment-related outcomes in hypertension. *Hypertension.* 2012;60(4):957-964.
68. Dorr M, Schmidt CO, Spielhagen T, et al. beta-blocker therapy and heart rate control during exercise testing in the general population: role of a common G-protein beta-3 subunit variant. *Pharmacogenomics.* 2010;11(9):1209-1221.

69. Yang YY, Lin HC, Lee WP, et al. Association of the G-protein and alpha2-adrenergic receptor gene and plasma norepinephrine level with clonidine improvement of the effects of diuretics in patients with cirrhosis with refractory ascites: a randomised clinical trial. *Gut*. 2010;59(11):1545-1553.
70. Nurnberger J, Dammer S, Mitchell A, et al. Effect of the C825T polymorphism of the G protein beta 3 subunit on the systolic blood pressure-lowering effect of clonidine in young, healthy male subjects. *Clin Pharmacol Ther*. 2003;74(1):53-60.
71. Fava C, von Wowern F, Berglund G, et al. 24-h ambulatory blood pressure is linked to chromosome 18q21-22 and genetic variation of NEDD4L associates with cross-sectional and longitudinal blood pressure in Swedes. *Kidney Int*. 2006;70(3):562-569.
72. Svensson-Farbom P, Wahlstrand B, Almgren P, et al. A functional variant of the NEDD4L gene is associated with beneficial treatment response with beta-blockers and diuretics in hypertensive patients. *J Hypertens*. 2011;29(2):388-395.
73. Luo F, Wang Y, Wang X, Sun K, Zhou X, Hui R. A functional variant of NEDD4L is associated with hypertension, antihypertensive response, and orthostatic hypotension. *Hypertens*. 2009;54(4):796-801.
74. McDonough CW, Burbage SE, Duarte JD, et al. Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics. *J Hypertens*. 2013;31(4):698-704.
75. Manunta P, Lavery G, Lanzani C, et al. Physiological interaction between alpha-adducin and WNK1-NEDD4L pathways on sodium-related blood pressure regulation. *Hypertens*. 2008;52(2):366-372.
76. Suonsyrja T, Hannila-Handelberg T, Fodstad H, Donner K, Kontula K, Hiltunen TP. Renin-angiotensin system and alpha-adducin gene polymorphisms and their relation to responses to antihypertensive drugs: results from the GENRES study. *Am J Hypertens*. 2009;22(2):169-175.
77. Turner ST, Chapman AB, Schwartz GL, Boerwinkle E. Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. *Am J Hypertens*. 2003;16(10):834-839.
78. Sciarrone MT, Stella P, Barlassina C, et al. ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy. *Hypertension*. 2003;41(3):398-403.
79. Glorioso N, Filigheddu F, Cusi D, et al. alpha-Adducin 460Trp allele is associated with erythrocyte Na transport rate in North Sardinian primary hypertensives. *Hypertension*. 2002;39(2 Pt 2):357-362.
80. Glorioso N, Manunta P, Filigheddu F, et al. The role of alpha-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study. *Hypertension*. 1999;34(4 Pt 1):649-654.
81. Cusi D, Barlassina C, Azzani T, et al. Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. *Lancet*. 1997;349(9062):1353-1357.
82. Yang YY, Lin HC, Lin MW, et al. Identification of diuretic non-responders with poor long-term clinical outcomes: a 1-year follow-up of 176 non-azotaemic cirrhotic patients with moderate ascites. *Clin Sci*. 2011;121(11):509-521.
83. Schelleman H, Klungel OH, Wittman JC, et al. Diuretic-gene interaction and the risk of myocardial infarction and stroke. *Pharmacogenomics J*. 2007;7(5):346-352.
84. Psaty BM, Smith NL, Heckbert SR, et al. Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. *JAMA*. 2002;287(13):1680-1689.
85. Gong Y, Wang Z, Beitelshees AL, et al. Pharmacogenomic Genome-Wide Meta-Analysis of Blood Pressure Response to beta-Blockers in Hypertensive African Americans. *Hypertens*. 2016.
86. Gong Y, McDonough CW, Beitelshees AL, et al. PTPRD gene associated with blood pressure response to atenolol and resistant hypertension. *J Hypertens*. 2015;33(11):2278-2285.
87. Hiltunen TP, Suonsyrja T, Hannila-Handelberg T, et al. Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study). *Am J Hypertens*. 2007;20(3):311-318.
88. Chapman AB, Schwartz GL, Boerwinkle E, Turner ST. Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension. *Kidney Int*. 2002;61(3):1047-1055.
89. Turner ST, Bailey KR, Fridley BL, et al. Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. *Hypertens*. 2008;52(2):359-365.
90. Duarte JD, Turner ST, Tran B, et al. Association of chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential YEATS4 expression. *Pharmacogenomics J*. 2013;13(3):257-263.

91. Turner ST, Boerwinkle E, O'Connell JR, et al. Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide. *Hypertens*. 2013;62(2):391-397.
92. Shuldiner AR, Relling MV, Peterson JF, et al. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. *Clin Pharmacol Ther*. 2013;94(2):207-210.
93. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. *J Clin Hypertens*. 2014;16(1):14-26.
94. Vandell AG, McDonough CW, Gong Y, et al. Hydrochlorothiazide-induced hyperuricaemia in the pharmacogenomic evaluation of antihypertensive responses study. *J Int Med*. 2014;276(5):486-497.
95. Wennerholm A, Dandara C, Sayi J, et al. The African-specific CYP2D6\*17 allele encodes an enzyme with changed substrate specificity. *Clin Pharmacol Ther*. 2002;71(1):77-88.
96. Wennerholm A, Johansson I, Hidestrand M, Bertilsson L, Gustafsson LL, Ingelman-Sundberg M. Characterization of the CYP2D6\*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity. *Pharmacogenetics*. 2001;11(5):417-427.
97. Grilo A, Saez-Rosas MP, Santos-Morano J, et al. Identification of genetic factors associated with susceptibility to angiotensin-converting enzyme inhibitors-induced cough. *Pharmacogenetics and genomics*. 2011;21(1):10-17.
98. Crews KR, Cross SJ, McCormick JN, et al. Development and implementation of a pharmacist-managed clinical pharmacogenetics service. *Am J Health-System Pharm*. 2011;68(2):143-150.
99. Weitzel KW, Alexander M, Bernhardt BA, et al. The IGNITE network: a model for genomic medicine implementation and research. *BMC Med Genomics*. 2016;9(1):1.
100. Peterson JF, Bowton E, Field JR, et al. Electronic health record design and implementation for pharmacogenomics: a local perspective. *Genet Med*. 2013;15(10):833-841.
101. O'Donnell PH, Danahey K, Jacobs M, et al. Adoption of a clinical pharmacogenomics implementation program during outpatient care--initial results of the University of Chicago "1,200 Patients Project". *Am J Med Genet. Part C, Seminars in medical genetics*. 2014;166C(1):68-75.
102. Levy KD, Decker BS, Carpenter JS, et al. Prerequisites to implementing a pharmacogenomics program in a large health-care system. *Clin Pharmacol Ther*. 2014;96(3):307-309.
103. Huntgeburth M, La Rosee K, ten Freyhaus H, et al. The Arg389Gly beta1-adrenoceptor gene polymorphism influences the acute effects of beta-adrenoceptor blockade on contractility in the human heart. *Clin Res Cardiol*. 2011;100(8):641-647.
104. Lobmeyer MT, Gong Y, Terra SG, et al. Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure. *Pharmacogenet Genomics*. 2007;17(4):277-282.
105. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. *Proc Natl Acad Sci*. 2006;103(30):11288-11293.
106. Terra SG, Hamilton KK, Pauly DF, et al. Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. *Pharmacogenet Genomics*. 2005;15(4):227-234.
107. Terra SG, Pauly DF, Lee CR, et al. beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. *Clin Pharmacol Ther*. 2005;77(3):127-137.
108. Liu J, Liu ZQ, Tan ZR, et al. Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol. *Clin Pharmacol Ther*. 2003;74(4):372-379.
109. Sofowora GG, Dishy V, Muszkat M, et al. A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. *Clin Pharmacol Ther*. 2003;73(4):366-371.
110. Liljedahl U, Lind L, Kurland L, Berglund L, Kahan T, Syvanen AC. Single nucleotide polymorphisms in the apolipoprotein B and low density lipoprotein receptor genes affect response to antihypertensive treatment. *BMC Cardiovasc Disord*. 2004;4(1):16.
111. McDonough CW, Gillis NK, Alsultan A, et al. Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. *PloS one*. 2013;8(10):e76984.
112. Gong Y, McDonough CW, Beitelshes AL, et al. PROX1 gene variant is associated with fasting glucose change after antihypertensive treatment. *Pharmacotherapy*. 2014;34(2):123-130.
113. Honda M, Ogura Y, Toyoda W, et al. Multiple regression analysis of pharmacogenetic variability of carvedilol disposition in 54 healthy Japanese volunteers. *Biol Pharm Bull*. 2006;29(4):772-778.

114. Yu HM, Lin SG, Liu GZ, Zhang YQ, Ma WJ, Deng CY. Associations between CYP11B2 gene polymorphisms and the response to angiotensin-converting enzyme inhibitors. *Clin Pharmacol Ther.* 2006;79(6):581-589.
115. Ortlepp JR, Hanrath P, Mevissen V, Kiel G, Borggrefe M, Hoffmann R. Variants of the CYP11B2 gene predict response to therapy with candesartan. *Eur J Pharmacol.* 2002;445(1-2):151-152.
116. Donner KM, Hiltunen TP, Hannila-Handelberg T, Suonsyrja T, Kontula K. STK39 variation predicts the ambulatory blood pressure response to losartan in hypertensive men. *Hypertens Res.* 2012;35(1):107-114.
117. Lee JK, Wu CK, Tsai CT, et al. Genetic variation-optimized treatment benefit of angiotensin-converting enzyme inhibitors in patients with stable coronary artery disease: a 12-year follow-up study. *Pharmacogenet Genomics.* 2013;23(4):181-189.
118. de Denus S, Zakrzewski-Jakubiak M, Dube MP, et al. Effects of AGTR1 A1166C gene polymorphism in patients with heart failure treated with candesartan. *Annals Pharmacother.* 2008;42(7):925-932.
119. Woo SW, Bang S, Chung MW, Jin SK, Kim YS, Lee SH. Lack of association between ACE and bradykinin B2 receptor gene polymorphisms and ACE inhibitor-induced coughing in hypertensive Koreans. *J Clin Pharm Ther.* 2009;34(5):561-567.
120. Mukae S, Itoh S, Aoki S, et al. Association of polymorphisms of the renin-angiotensin system and bradykinin B2 receptor with ACE-inhibitor-related cough. *J Hum Hypertens.* 2002;16(12):857-863.
121. Lee YJ, Tsai JC. Angiotensin-converting enzyme gene insertion/deletion, not bradykinin B2 receptor -58T/C gene polymorphism, associated with angiotensin-converting enzyme inhibitor-related cough in Chinese female patients with non-insulin-dependent diabetes mellitus. *Metabolism.* 2001;50(11):1346-1350.
122. Mukae S, Aoki S, Itoh S, Iwata T, Ueda H, Katagiri T. Bradykinin B(2) receptor gene polymorphism is associated with angiotensin-converting enzyme inhibitor-related cough. *Hypertens.* 2000;36(1):127-131.
123. Silva PS, Fontana V, Luizon MR, et al. eNOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril. *Eur J Clin Pharmacol.* 2013;69(2):167-177.
124. Mas S, Gasso P, Alvarez S, et al. Pharmacogenetic predictors of angiotensin-converting enzyme inhibitor-induced cough: the role of ACE, ABO, and BDKRB2 genes. *Pharmacogenet Genomics.* 2011;21(9):531-538.
125. Luo JQ, He FZ, Luo ZY, et al. Rs495828 polymorphism of the ABO gene is a predictor of enalapril-induced cough in Chinese patients with essential hypertension. *Pharmacogenet Genomics.* 2014;24(6):306-313.
126. Oliveira-Paula GH, Lacchini R, Fontana V, Silva PS, Biagi C, Tanus-Santos JE. Polymorphisms in VEGFA gene affect the antihypertensive responses to enalapril. *Eur J Clin Pharmacol.* 2015;71(8):949-957.
127. Luo JQ, Wang LY, He FZ, et al. Effect of NR3C2 genetic polymorphisms on the blood pressure response to enalapril treatment. *Pharmacogenomics.* 2014;15(2):201-208.
128. Bhatnagar V, O'Connor DT, Schork NJ, et al. Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial. *J Hypertens.* 2007;25(10):2082-2092.
129. Su X, Lee L, Li X, et al. Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor. *Circulation.* 2007;115(6):725-732.
130. Zhang Y, Hong XM, Xing HX, Li JP, Huo Y, Xu XP. E112D polymorphism in the prolylcarboxypeptidase gene is associated with blood pressure response to benazepril in Chinese hypertensive patients. *Chin Med J.* 2009;122(20):2461-2465.
131. Kamide K, Asayama K, Katsuya T, et al. Genome-wide response to antihypertensive medication using home blood pressure measurements: a pilot study nested within the HOMED-BP study. *Pharmacogenomics.* 2013;14(14):1709-1721.
132. Bremer T, Man A, Kask K, Diamond C. CACNA1C polymorphisms are associated with the efficacy of calcium channel blockers in the treatment of hypertension. *Pharmacogenomics.* 2006;7(3):271-279.
133. Hamrefors V, Sjogren M, Almgren P, et al. Pharmacogenetic implications for eight common blood pressure-associated single-nucleotide polymorphisms. *J Hypertens.* 2012;30(6):1151-1160.
134. Beitelshes AL, Gong Y, Wang D, et al. KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST). *Pharmacogenet Genomics.* 2007;17(9):719-729.
135. Zhao Q, Wang L, Yang W, et al. Interactions among genetic variants from contractile pathway of vascular smooth muscle cell in essential hypertension susceptibility of Chinese Han population. *Pharmacogenet Genomics.* 2008;18(6):459-466.
136. Nielsen T, Burgdorf KS, Grarup N, et al. The KCNMB1 Glu65Lys polymorphism associates with reduced systolic and diastolic blood pressure in the Inter99 study of 5729 Danes. *J Hypertens.* 2008;26(11):2142-2146.

137. Price ET, Pacanowski MA, Martin MA, et al. Liver X receptor alpha gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study. *Pharmacogenet Genomics*. 2011;21(6):333-340.
138. van Noord C, Aarnoudse AJ, Eijgelsheim M, et al. Calcium channel blockers, NOS1AP, and heart-rate-corrected QT prolongation. *Pharmacogenet Genomics*. 2009;19(4):260-266.
139. Hong X, Xing H, Yu Y, et al. Genetic polymorphisms of the urea transporter gene are associated with antihypertensive response to nifedipine GITS. *Methods Find Exp Clin Pharmacol*. 2007;29(1):3-10.
140. Karnes JH, McDonough CW, Gong Y, et al. Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment. *Pharmacogenomics J*. 2013;13(5):430-436.
141. Karnes JH, Gong Y, Pacanowski MA, et al. Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes. *Pharmacogenet Genomics*. 2013;23(12):697-705.
142. Kurland L, Liljedahl U, Karlsson J, et al. Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. *Am J Hypertens*. 2004;17(1):8-13.
143. Yu H, Lin S, Zhong J, et al. A core promoter variant of angiotensinogen gene and interindividual variation in response to angiotensin-converting enzyme inhibitors. *J Renin Angiotensin-Aldosterone Syst*. 2014;15(4):540-546.
144. Kurland L, Melhus H, Karlsson J, et al. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. *J Hypertens*. 2001;19(10):1783-1787.
145. Liljedahl U, Kahan T, Malmqvist K, et al. Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihypertensive treatment. *J Hypertens*. 2004;22(12):2321-2328.
146. Toyofyuku M, Imazu M, Sumii K, et al. Influence of angiotensinogen M253T gene polymorphism and an angiotensin converting enzyme inhibitor on restenosis after percutaneous coronary intervention. *Atheroscler*. 2002;160(2):339-344.
147. Bis JC, Smith NL, Psaty BM, et al. Angiotensinogen Met235Thr polymorphism, angiotensin-converting enzyme inhibitor therapy, and the risk of nonfatal stroke or myocardial infarction in hypertensive patients. *Am J Hypertens*. 2003;16(12):1011-1017.
148. Sookoian S, Castano G, Garcia SI, Viudez P, Gonzalez C, Pirola CJ. A1166C angiotensin II type 1 receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension. *Am J Gastroenterol*. 2005;100(3):636-642.
149. Benetos A, Cambien F, Gautier S, et al. Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals. *Hypertens*. 1996;28(6):1081-1084.
150. Miller JA, Thai K, Scholey JW. Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II. *Kidney Int*. 1999;56(6):2173-2180.
151. Jiang S, Hsu YH, Venners SA, et al. Interactive effect of angiotensin II type 1 receptor (AGT1R) polymorphisms and plasma irbesartan concentration on antihypertensive therapeutic responses to irbesartan. *J Hypertens*. 2011;29(5):890-895.
152. Frazier L, Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. Multilocus effects of the renin-angiotensin-aldosterone system genes on blood pressure response to a thiazide diuretic. *Pharmacogenomics J*. 2004;4(1):17-23.
153. Spiering W, Kroon AA, Fuss-Lejeune MJ, de Leeuw PW. Genetic contribution to the acute effects of angiotensin II type 1 receptor blockade. *J Hypertens*. 2005;23(4):753-758.
154. Felehgari V, Rahimi Z, Mozafari H, Vaisi-Raygani A. ACE gene polymorphism and serum ACE activity in Iranians type II diabetic patients with macroalbuminuria. *Mol Cell Biochem*. 2011;346(1-2):23-30.
155. Ciccoira M, Rossi A, Bonapace S, et al. Effects of ACE gene insertion/deletion polymorphism on response to spironolactone in patients with chronic heart failure. *Am J Med*. 2004;116(10):657-661.
156. Potaczek DP, Undas A, Iwaniec T, Szczeklik A. The angiotensin-converting enzyme gene insertion/deletion polymorphism and effects of quinapril and atorvastatin on haemostatic parameters in patients with coronary artery disease. *J Thromb Haemost*. 2005;94(1):224-225.
157. Perez-Castrillon JL, Silva J, Justo I, et al. Effect of quinapril, quinapril-hydrochlorothiazide, and enalapril on the bone mass of hypertensive subjects: relationship with angiotensin converting enzyme polymorphisms. *Am J Hypertens*. 2003;16(6):453-459.

158. Prasad A, Narayanan S, Husain S, et al. Insertion-deletion polymorphism of the ACE gene modulates reversibility of endothelial dysfunction with ACE inhibition. *Circulation*. 2000;102(1):35-41.
159. Haas M, Yilmaz N, Schmidt A, et al. Angiotensin-converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease. Austrian Study Group of the Effects of Enalapril Treatment in Proteinuric Renal Disease. *Kidney Blood Press Res*. 1998;21(1):66-69.
160. Sasaki M, Oki T, Iuchi A, et al. Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies. *J Hypertens*. 1996;14(12):1403-1408.
161. van Essen GG, Rensma PL, de Zeeuw D, et al. Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy. *Lancet*. 1996;347(8994):94-95.
162. He H, Li LM, Cao WH, Sun NL, Liu MZ, Hu YH. A study of the relationships between angiotensin-converting enzyme gene, chymase gene polymorphisms, pharmacological treatment with ACE inhibitor and regression of left ventricular hypertrophy in essential hypertension patients treated with benazepril. *Ann Hum Biol*. 2005;32(1):30-43.
163. Ha SK, Yong Lee S, Su Park H, et al. ACE DD genotype is more susceptible than ACE II and ID genotypes to the antiproteinuric effect of ACE inhibitors in patients with proteinuric non-insulin-dependent diabetes mellitus. *Nephrol Dial Transplant*. 2000;15(10):1617-1623.
164. Wu CK, Luo JL, Tsai CT, et al. Demonstrating the pharmacogenetic effects of angiotensin-converting enzyme inhibitors on long-term prognosis of diastolic heart failure. *Pharmacogenom J*. 2010;10(1):46-53.
165. Penno G, Chaturvedi N, Talmud PJ, et al. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM. *Diabetes*. 1998;47(9):1507-1511.
166. Fan X, Wang Y, Sun K, et al. Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Captopril in women. *Clinical pharmacology and therapeutics*. 2007;82(2):187-196.
167. Sandrim VC, Palei AC, Luizon MR, Izidoro-Toledo TC, Cavalli RC, Tanus-Santos JE. eNOS haplotypes affect the responsiveness to antihypertensive therapy in preeclampsia but not in gestational hypertension. *Pharmacogenom J*. 2010;10(1):40-45.
168. Cruz-Gonzalez I, Corral E, Sanchez-Ledesma M, Sanchez-Rodriguez A, Martin-Luengo C, Gonzalez-Sarmiento R. Association between -T786C NOS3 polymorphism and resistant hypertension: a prospective cohort study. *BMC Cardiovasc Disord*. 2009;9:35.
169. Lynch AI, Boerwinkle E, Davis BR, et al. Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension. *Jama*. 2008;299(3):296-307.
170. Beitelshes AL, Navare H, Wang D, et al. CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response. *Circ Cardiovasc Genet*. 2009;2(4):362-370.
171. Sherva R, Ford CE, Eckfeldt JH, Davis BR, Boerwinkle E, Arnett DK. Pharmacogenetic effect of the stromelysin (MMP3) polymorphism on stroke risk in relation to antihypertensive treatment: the genetics of hypertension associated treatment study. *Stroke*. 2011;42(2):330-335.